Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 8/2006

01-08-2006 | Current Opinion

Antibacterial Dosing in Intensive Care

Pharmacokinetics, Degree of Disease and Pharmacodynamics of Sepsis

Authors: Jason A. Roberts, Prof. Jeffrey Lipman

Published in: Clinical Pharmacokinetics | Issue 8/2006

Login to get access

Abstract

Treatment of sepsis remains a significant challenge with persisting high mortality and morbidity. Early and appropriate antibacterial therapy remains an important intervention for such patients. To optimise antibacterial therapy, the clinician must possess knowledge of the pharmacokinetic and pharmacodynamic properties of commonly used antibacterials and how these parameters may be affected by the constellation of pathophysiological changes occurring during sepsis.
Sepsis, and the treatment thereof, increases renal preload and, via capillary permeability, leads to ‘third-spacing’, both resulting in higher antibacterial clearances. Alternatively, sepsis can induce multiple organ dysfunction, including renal and/or hepatic dysfunction, causing a decrease in antibacterial clearance.
Aminoglycosides are concentration-dependent antibacterials and they display an increased volume of distribution (Vd) in sepsis, resulting in decreased peak serum concentrations. Reduced clearance from renal dysfunction would increase the likelihood of toxicity. Individualised dosing using extended interval dosing, which maximises the peak serum drug concentration (Cmax)/minimum inhibitory concentration ratio is recommended.
β-Lactams and carbapenems are time-dependent antibacterials. An increase in Vd and renal clearance will require increased dosing or administration by continuous infusion. If renal impairment occurs a corresponding dose reduction may be required.
Vancomycin displays predominantly time-dependent pharmacodynamic properties and probably requires higher than conventionally recommended doses because of an increased Vd and clearance during sepsis without organ dysfunction. However, optimal dosing regimens remain unresolved. The poor penetration of vancomycin into solid organs may require alternative therapies when sepsis involves solid organs (e.g. lung).
Ciprofloxacin displays largely concentration-dependent kill characteristics, but also exerts some time-dependent effects. The Vd of ciprofloxacin is not altered with fluid shifts or over time, and thus no alterations of standard doses are required unless renal dysfunction occurs.
In order to optimise antibacterial regimens in patients with sepsis, the pathophysiological effects of systemic inflammatory response syndrome need consideration, in conjunction with knowledge of the different kill characteristics of the various antibacterial classes.
In conclusion, certain antibacterials can have a very high Vd, therefore leading to a low Cmax and if a high peak is needed, then this would lead to underdosing. The Vd of certain antibacterials, namely aminoglycosides and vancomycin, changes over time, which means dosing may need to be altered over time. Some patients with serum creatinine values within the normal range can have very high drug clearances, thereby producing low serum drug levels and again leading to underdosing.
Literature
1.
Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001 Jul; 29 (7 Suppl.): S99–106PubMedCrossRef
2.
Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997 Jul; 25(7): 1095–100PubMedCrossRef
3.
Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 Apr 17; 348(16): 1546–54PubMedCrossRef
4.
Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 Jul; 29(7): 1303–10PubMedCrossRef
5.
Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005; 56: 225–48PubMedCrossRef
6.
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Al-modovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003 Dec; 31(12): 2742–51PubMedCrossRef
7.
Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999 Feb; 115(2): 462–74PubMedCrossRef
8.
Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115(7): 529–35PubMedCrossRef
9.
MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004; 38(2): 284–8PubMedCrossRef
10.
Cunha BA. Antibiotic treatment of sepsis. Med Clin North Am 1995 May; 79(3): 551–8PubMed
11.
Nicolau DP. Optimizing antimicrobial therapy and emerging pathogens. Am J Manag Care 1998; 4 (10 Suppl. 2): S525–30
12.
Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 2003 Dec; 9(4): 292–6PubMedCrossRef
13.
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992 Jun; 101(6): 1644–55PubMedCrossRef
14.
Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005 Jul; 33(7): 1538–48PubMedCrossRef
15.
Hugonnet S, Harbarth S, Ferriere K, et al. Bacteremic sepsis in intensive care: temporal trends in incidence, organ dysfunction, and prognosis. Crit Care Med 2003 Feb; 31(2): 390–4PubMedCrossRef
16.
Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001 Feb; 29(2): 385–91PubMedCrossRef
17.
Kieft H, Hoepelman AI, Knupp CA, et al. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993 Nov; 32 Suppl. B: 117–22PubMedCrossRef
18.
19.
Grocott-Mason RM, Shah AM. Cardiac dysfunction in sepsis: new theories and clinical implications. Intensive Care Med 1998; 24: 286–95PubMedCrossRef
20.
21.
Nuytinck HK, Offermans XJ, Kubat K, et al. Whole-body inflammation in trauma patients: an autopsy study. Arch Surg 1988 Dec; 123(12): 1519–24PubMedCrossRef
22.
Gosling P, Sanghera K, Dickson G. Generalized vascular permeability and pulmonary function in patients following serious trauma. J Trauma 1994 Apr; 36(4): 477–81PubMedCrossRef
23.
Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990 Aug 1; 113(3): 227–42PubMed
24.
Pea F, Porreca L, Baraldo M, et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 Mar; 45(3): 329–35PubMedCrossRef
25.
Di Giantomasso D, Bellomo R, May CN. The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock. Intensive Care Med 2005; 31(3): 454–62PubMedCrossRef
26.
Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow. Intensive Care Med 2002; 28(12): 1804–9PubMedCrossRef
27.
Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. Intensive Care Med 2003; 29(10): 1774–81PubMedCrossRef
28.
Lipman J, Gous AG, Mathivha LR, et al. Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? Intensive Care Med 2002 Apr; 28(4): 493–500PubMedCrossRef
29.
Lipman J, Wallis SC, Rickard CM, et al. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001 Feb; 27(2): 363–70PubMedCrossRef
30.
Lipman J, Wallis S, Boots R. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Anaig 2003 Oct; 97(4): 1149–54CrossRef
31.
Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002 Apr; 30(2): 134–44PubMed
32.
Power BM, Forbes AM, van Heerden PV, et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998 Jan; 34(1): 25–56PubMedCrossRef
33.
Livornese LL, Slavin D, Benz RL, et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2001 Sep; 15(3): 983–1002PubMedCrossRef
34.
Livornese LL, Slavin D, Gilbert B, et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2004; 18: 551–79PubMedCrossRef
35.
Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005 Oct 15; 41(8): 1159–66PubMedCrossRef
36.
Joy MS, Matzke GR, Frye RF, et al. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 1998 Jun; 31(6): 1019–27PubMedCrossRef
37.
Joy MS, Matzke GR, Armstrong DK, et al. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998 Mar; 32(3): 362–75PubMedCrossRef
38.
Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001 Sep; 45(8): 929–34PubMedCrossRef
39.
Schetz M, Ferdinande P, Van den Berghe G, et al. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995 Jul; 21(7): 612–20PubMedCrossRef
40.
Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993 May; 24(5): 362–79PubMedCrossRef
41.
Freebairn RC, Lipman J. Renal replacement therapy for the critically ill: precarious progress. Part I. Definitions and physiological aspects. S Afr J Surg 1993 Sep; 31(3): 114–20PubMed
42.
Freebairn RC, Lipman J. Renal replacement therapy for the critically ill: precarious progress. Part II. Technical aspects and clinical application. S Afr J Surg 1993 Dec; 31(4): 147–51PubMed
43.
Cotterill S. Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother 1995 Nov; 36(5): 773–80PubMedCrossRef
44.
Bressolle F, Kinowski JM, de la Coussaye JE, et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994 Jun; 26(6): 457–71PubMedCrossRef
45.
Gunderson BW, Ross GH, Ibrahim KH, et al. What do we really know about antibiotic pharmacodynamics. Pharmacotherapy 2001; 21(11s): 302–18CrossRef
46.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998 Jan; 26(1): 1–10PubMedCrossRef
47.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9PubMedCrossRef
48.
Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993 May; 37(5): 1073–81PubMedCrossRef
49.
Chambers HE, Sande MA. Goodman and Gillman’s The pharmacological basis of therapeutics. New York: McGraw Hill, 1996: 1103–21
50.
Dager WE. Aminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups. Ann Pharmacother 1994 Jul-Aug; 28(7-8): 944–51PubMed
51.
Mangione A, Schentag JJ. Therapeutic monitoring of aminoglycoside antibiotics: an approach. Ther Drug Monit 1980; 2(2): 159–67PubMedCrossRef
52.
Pharmacia Australia. Product Information: gentamicin injection BP (R), gentamicin sulphate. Rydalmere (NSW): 2005
53.
Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993 Feb 6; 341(8841): 335–9PubMedCrossRef
54.
Burton ME, Brater DC, Chen PS, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985 Mar; 37(3): 349–57PubMedCrossRef
55.
Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997 Feb; 43(2): 125–35PubMedCrossRef
56.
Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995 Mar; 39(3): 650–5PubMedCrossRef
57.
Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995 Jun; 39(6): 605–9PubMedCrossRef
58.
Kirkpatrick CM, Duffull SB, Begg EJ, et al. The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther Drug Monit 2003 Oct; 25(5): 623–30PubMedCrossRef
59.
Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999 Oct; 43(10): 2559–61PubMed
60.
Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992 Mar; 36(3): 552–7PubMedCrossRef
61.
Levitt DG. The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003; 3: 3–32PubMedCrossRef
62.
Stoeckel K. Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy 1981; 27 Suppl. 1: 42–6PubMedCrossRef
63.
64.
Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000 Sep; 39(3): 185–201PubMedCrossRef
65.
66.
Fernandez de Gatta MD, Calvo MV, Hernandez JM, et al. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996 Sep; 60(3): 332–40CrossRef
67.
MIMS Australia. Ciproxin (R) product information. In: Donohoo E, editor. MIMS online. St Leonards, NSW: CMPMedica Australia Pty Ltd, 2005
68.
Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure. 3rd ed. Philadelphia (PA): American College of Physicians, 1994
69.
Brittain DC, Scully BE, McElrath MJ, et al. The pharmacology of orally administered ciprofloxacin. Drugs Exp Clin Res 1985; 11(5): 339–41PubMed
70.
Rodvold KA. Pharmacodynamics of antiinfective therapy: taking what we know to the patient’s bedside. Pharmacotherapy 2001; 21(11s): 319–30CrossRef
71.
Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1991; 74: 63–70
72.
Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831–47PubMedCrossRef
73.
74.
Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985; 15 Suppl A (1): 37–46PubMedCrossRef
75.
Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, et al. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989; 8(10): 878–87PubMedCrossRef
76.
Bakker-Woudenberg IA, Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med 1990; 16 Suppl. 3: S229–34PubMedCrossRef
77.
Craig W. Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients. Eur J Clin Microbiol Infect Dis 1984; 3: 575–8CrossRef
78.
Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44(2): 201–10PubMedCrossRef
79.
Turnidge J. Pharmcokinetics and pharmacodynamics of fluoroquinolones. Drugs 1998; 58 Suppl. 2: 29–36
80.
81.
Fisman DN, Kaye KM. Once daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am 2000 Jun; 14(2): 475–87PubMedCrossRef
82.
Kapusnik JE, Hackbarth CJ, Chambers HF, et al. Single, large, daily dosing versus intermittent dosing of tobramycin fro treating experimental pseudomonas pneumonia. J Infect Dis 1988; 158: 7–12PubMedCrossRef
83.
Klatersky J. Concept of empiric therapy with antibiotic combinations; indications and limits. Am J Med 1986; 80 Suppl. 5C: 2–12
84.
Thorburn CE, Molesworth SJ, Sutherland R, et al. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob Agents Chemother 1996 Dec; 40(12): 2796–801PubMed
85.
Lavigne JP, Bonnet R, Michaux-Charachon S, et al. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria. J Antimicrob Chemother 2004 Apr; 53(4): 616–9PubMedCrossRef
86.
Zhanel GG, Ariano RE. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity? Ren Fail 1992; 14: 1–9PubMedCrossRef
87.
Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997 May; 24(5): 796–809PubMedCrossRef
88.
Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997 May; 24(5): 786–95PubMedCrossRef
89.
Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996 Apr; 37(4): 645–63PubMedCrossRef
90.
Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996 Feb 10; 312(7027): 338–45PubMedCrossRef
91.
Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004; 32(8): 1678–82PubMedCrossRef
92.
Leggett JE, Fantin B, Ebert S. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281–92PubMedCrossRef
93.
Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77(6A): 43–50PubMed
94.
Bouvier d’Yvoire MJY, Maire PH. Dosage regimens of antibacterials: implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Invest 1996; 11: 229–39CrossRef
95.
Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP 1989 Oct; 23(10): 788–94PubMed
96.
Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991 Mar; 35(3): 399–405PubMedCrossRef
97.
Marik PE, Havlik I, Monteagudo FS, et al. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother 1991 May; 27 Suppl. C: 81–9PubMedCrossRef
98.
Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991 Nov; 28(5): 753–64PubMedCrossRef
99.
Van der Auwera P, Meunier F, Ibrahim S, et al. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/ kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991 Apr; 35(4): 640–7PubMedCrossRef
100.
Mann HJ, Fuhs DW, Awang R, et al. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987 Feb; 6(2): 148–53PubMed
101.
Fuhs DW, Mann HJ, Kubajak CA, et al. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients. Clin Pharm 1988 Mar; 7(3): 207–13PubMed
102.
Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med 1987 Dec; 15(12): 1143–5PubMedCrossRef
103.
Chelluri L, Warren J, Jastremski MS. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients. Chest 1989 Jun; 95(6): 1295–7PubMedCrossRef
104.
Townsend PL, Fink MP, Stein KL, et al. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989 Feb; 17(2): 154–7PubMedCrossRef
105.
Reed II RL, Wu AH, Miller-Crotchett P, et al. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma 1989 Nov; 29(11): 1462–8PubMedCrossRef
106.
Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988 Apr; 16(4): 327–30PubMedCrossRef
107.
Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16(5): 303–6PubMedCrossRef
108.
Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980 Feb; 87(2): 164–9PubMed
109.
Beckhouse MJ, Whyte IM, Byth PL, et al. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988 Nov; 16(4): 418–22PubMed
110.
Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002 Jul; 28(7): 936–42PubMedCrossRef
111.
Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993 Apr; 21(2): 172–3PubMed
112.
Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993 May; 31 Suppl. D: 149–58PubMedCrossRef
113.
McDonald P, Wetherall B, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3: 38–44PubMedCrossRef
114.
Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglcyosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997; 24: 810–5PubMedCrossRef
115.
Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27: 32–48PubMedCrossRef
116.
Kashuba ADM, Nafiziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623–9PubMed
117.
Lipman J, Crewe-Brown HH, Saunders GL, et al. Subtleties of antibiotic dosages: do doses and intervals make a difference in the critically ill? S Afr J Surg 1996 Nov; 34(4): 160–2PubMed
118.
Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997 Apr; 41(4): 733–8PubMed
119.
Fantin B, Farinotti R, Thabaut A, et al. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother 1994 Mar; 33(3): 563–9PubMedCrossRef
120.
121.
Tessier PR, Nicolau DP, Onyeji CO, et al. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy 1999 Jul-Aug; 45(4): 284–95PubMedCrossRef
122.
Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2004 Apr; 2(4): 289–300PubMedCrossRef
123.
Bustamante CI, Drusano GL, Tatem BA, et al. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984 Nov; 26(5): 678–82PubMedCrossRef
124.
Fantin B, Ebert S, Leggett J, et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1991 Jun; 27(6): 829–36PubMedCrossRef
125.
Gudmundsson S, Vogelman B, Craig WA. The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986 Dec; 18 Suppl. E: 67–73PubMed
126.
Tauber MG, Zak O, Scheid WM, et al. The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J Infect Dis 1984 Apr; 149(4): 575–83PubMedCrossRef
127.
Angus BJ, Smith MD, Suputtamongkol Y, et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000 Aug; 50(2): 184–91PubMedCrossRef
128.
Mouton JW, den Hollander JG. Killing of pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994 May; 38(5): 931–6PubMedCrossRef
129.
Young RJ, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997 Aug; 40(2): 269–73PubMedCrossRef
130.
Lipman J, Gomersall CD, Gin T, et al. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999 Feb; 43(2): 309–11PubMedCrossRef
131.
MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998 Nov; 35(5): 391–402PubMedCrossRef
132.
Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000 Jan; 22(1): 66–75PubMedCrossRef
133.
Tam VH, Louie A, Lomaestro BM, et al. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003 Mar; 23(3): 291–5PubMedCrossRef
134.
Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003 Aug; 31(8): 2102–6PubMedCrossRef
135.
Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia. J Pharm Pharmacol 2002 Dec; 54(12): 1693–6PubMedCrossRef
136.
Georges B, Archambaud M, Saivin S, et al. Continuous versus intermittent cefepime infusion in critical care: preliminary results. Pathol Biol (Paris) 1999 May; 47(5): 483–5
137.
Fry DE. The importance of antibiotic pharmacokinetics in critical illness. Am J Surg 1996 Dec; 172(6A): 20S–5SPubMedCrossRef
138.
Lorente L, Garcia C, Martin M, et al. Continuous infusion versus intermitted infusion of ceftazidime for the treatment of pneumonia caused by Pseudomonas aeruginosa. 25th International Symposium on Intensive Care and Emergency Medicine; 2005 Mar 21-25; Brussels
139.
Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001 Jun; 17(6): 497–504PubMedCrossRef
140.
McNabb JJ, Nightingale CH, Quintiliani R, et al. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001 May; 21(5): 549–55PubMedCrossRef
141.
Krueger WA, Lenhart FP, Neeser G, et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2002 Oct 15; 166(8): 1029–37PubMedCrossRef
142.
Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996 Mar; 40(3): 691–5PubMed
143.
Zeisler JA, McCarthy JD, Richelieu WA, et al. Cefuroxime by continuous infusion: a new standard of care? Infect Med 1992; 9: 54–60
144.
Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillintazobactam program in a large community teaching hospital. Pharmacotherapy 2002 Apr; 22(4): 471–83PubMedCrossRef
145.
Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. Am J Health Syst Pharm 2003 Nov 15; 60(22): 2321–7PubMed
146.
Nicolau DP, Nightingale CH, Banevicius MA, et al. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996 Jan; 40(1): 61–4PubMed
147.
Buck C, Bertram N, Ackermann T, et al. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005 Jan; 25(1): 62–7PubMedCrossRef
148.
Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005 Sep; 5(9): 581–9PubMedCrossRef
149.
Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000 Jun; 179(6): 436–40PubMedCrossRef
150.
Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999 Jul; 43(7): 1798–802PubMed
151.
Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001 Apr; 47(4): 421–9PubMedCrossRef
152.
Roberts JA, Lipman J, Rickard C, et al. Continuous infusion of ceftriaxone has clinical and bacteriologic advantages over bolus dosing in patients with sepsis. Society of Hospital Pharmacists of Australia - Federal Conference; 2005, Brisbane
153.
Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479–501PubMedCrossRef
154.
Roosendaal R, Bakker-Woudenberg IA, Van den Berghe JC, et al. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986; 30: 403–8PubMedCrossRef
155.
Barrons RW, Murray KM, Richey RM. Populations at risk for penicillin-induced seizures. Ann Pharmacother 1992 Jan; 26(1): 26–9PubMed
156.
Day IP, Goudie J, Nishiki K, et al. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995 Apr; 76(3): 239–43PubMedCrossRef
157.
Laethem T, De Lepeleire I, McCrea J, et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother 2003 Apr; 47(4): 1439–42PubMedCrossRef
158.
Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 207–23PubMedCrossRef
159.
Hirouchi Y, Naganuma H, Kawahara Y, et al. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn J Pharmacol 1994; 66(1): 1–6PubMedCrossRef
160.
Gibson TP, Demetriades JL, Bland JA. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med 1985 Jun 7; 78(6A): 54–61PubMedCrossRef
161.
Leroy A, Fillastre JP, Etienne I, et al. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 1992; 42(5): 535–8PubMedCrossRef
162.
Konishi K, Suzuki H, Saruta T, et al. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. Antimicrob Agents Chemother 1991 Aug; 35(8): 1616–20PubMedCrossRef
163.
Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003 Jan 15; 36 Suppl. 1: S42–50PubMedCrossRef
164.
Kotapati S, Nicolau DP, Nightingale CH, et al. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2004 Jun 15; 61(12): 1264–70PubMed
165.
Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992 Dec; 36(12): 2577–83PubMedCrossRef
166.
Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002; 20(8): 513–28PubMedCrossRef
167.
Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999 Apr; 43(4): 523–7PubMedCrossRef
168.
Keil S, Wiedemann B. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother 1997 Jun; 41(6): 1215–9PubMed
169.
Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44(5): 539–49PubMedCrossRef
170.
Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002 Feb; 19(2): 105–10PubMedCrossRef
171.
Jaruratanasirikul S, Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health 2003 Sep; 34: 627–9PubMed
172.
Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 Aug; 46(8): 2327–32PubMedCrossRef
173.
Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005; 49(5): 1881–9PubMedCrossRef
174.
Kuti JL, Nightingale CH, Knauft RF, et al. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004; 26(4): 493–501PubMedCrossRef
175.
Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005 Apr; 49(4): 1337–9PubMedCrossRef
176.
Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40(2): 219–23PubMedCrossRef
177.
Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006 Jan 1; 42 Suppl. 1: S35–9PubMedCrossRef
178.
Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998 Dec 15; 83(12): 2597–607PubMedCrossRef
179.
Riley Jr HD. Vancomycin and novobiocin. Med Clin North Am 1970 Sep; 54(5): 1277–89PubMed
180.
Brogden RN, Peters DH. Teicoplanin: a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994 May; 47(5): 823–54PubMedCrossRef
181.
Barbot A, Venisse N, Rayeh F, et al. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003 Sep; 29(9): 1528–34PubMedCrossRef
182.
183.
Larsson AJ, Walker KJ, Raddatz JK, et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996 Oct; 38(4): 589–97PubMedCrossRef
184.
185.
Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998 Oct; 42(10): 2739–44PubMed
186.
Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bacterial rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990; 47: 2018–21
187.
Duffull SB, Begg EJ, Chambers ST, et al. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob Agents Chemother 1994; 38: 2480–2PubMedCrossRef
188.
Knudsen JD, Fuursted K, Raber S, et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44: 1247–54PubMedCrossRef
189.
Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001 Sep; 45(9): 2460–7PubMedCrossRef
190.
Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005 Sep; 33(9): 1983–7PubMedCrossRef
191.
Gous AG, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995 Dec; 23(6): 678–82PubMed
192.
Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984 Apr; 25(4): 433–7PubMedCrossRef
193.
MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998 Oct; 20(5): 473–7PubMedCrossRef
194.
James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996; 40: 696–700PubMed
195.
Bodi M, Ardanuy C, Olona M, et al. Therapy of ventilator-associated pneumonia: the Tarragona strategy. Clin Microbiol Infect 2001 Jan; 7(1): 32–3PubMedCrossRef
196.
Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996 Nov; 38(5): 865–9PubMedCrossRef
197.
198.
Conte JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 26: 1475–80CrossRef
199.
Peterson LR. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline. Diagn Microbiol Infect Dis 2005 Jul; 52(3): 163–4PubMedCrossRef
200.
Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005 Oct; 49(10): 4344–6PubMedCrossRef
201.
Hoffken G, Lode H, Prinzing C, et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985 Mar; 27(3): 375–9PubMedCrossRef
202.
Jones EM. The pharmacokinetics of intravenous ciprofloxacin 400mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997; 40: 121–4PubMedCrossRef
203.
Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997 Jul; 41(7): 1562–5PubMed
204.
Chien SC, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998 Apr; 42(4): 885–8PubMed
205.
Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995 Dec; 39(12): 2635–40PubMedCrossRef
206.
Preston SL, Drusano GL, Berman AL. Pharmaco-dynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125–9PubMedCrossRef
207.
Piddock LJ, Dalhoff A. Should quinolones be used in the treatment of bacterial infections in neutropenic patients? J Antimicrob Chemother 1993 Nov; 32(5): 771–4PubMedCrossRef
208.
Nix DE, Spivey JM, Norman A, et al. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. Ann Pharmacother 1992 Jan; 26(1): 8–10PubMed
209.
Goss TF, Forrest A, Nix DE, et al. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994 Jul-Aug; 28(7–8): 863–8PubMed
210.
Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000 Aug; 182(2): 517–25PubMedCrossRef
211.
MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. J Antimicrob Chemother 2000 Aug; 46(2): 163–70PubMedCrossRef
212.
Hyatt JM, Schentag JJ. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2000 Jan; 21 (1 Suppl.): S9–11PubMedCrossRef
213.
Thomas JK, Forrest A, Bhavani SM, et al. Pharmaco-dynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521–7PubMed
214.
Schentag JJ. Antimicrobial action and pharmaco-kinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11: 426–39PubMed
215.
Gous A, Lipman J, Scribante J, et al. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005 Jul; 26(1): 50–5PubMedCrossRef
216.
Lipman J, Scribante J, Gous AG, et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998 Sep; 42(9): 2235–9PubMed
Metadata
Title
Antibacterial Dosing in Intensive Care
Pharmacokinetics, Degree of Disease and Pharmacodynamics of Sepsis
Authors
Jason A. Roberts
Prof. Jeffrey Lipman
Publication date
01-08-2006
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2006
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200645080-00001

Other articles of this Issue 8/2006

Clinical Pharmacokinetics 8/2006 Go to the issue

Original Research Article

Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects

Correspondence

The Author’s Reply

Original Research Article

Lack of Pharmacokinetic Interaction for ISIS 113715, a 2′-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone

Correspondence

Parametric and Nonparametric Population Methods

Original Research Article

Comparison of Equivalent Doses of Fentanyl Buccal Tablets and Arteriovenous Differences in Fentanyl Pharmacokinetics

Leading Article

Chronopharmacokinetics of Ciclosporin and Tacrolimus